Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 170

1.

The challenge of chronic hepatitis E in liver transplant recipients: Failure of sofosbuvir plus ribavirin therapy.

Sastre L, García-López M, Pérez-Del-Pulgar S, Lens S, Costa J, Navasa M, Forns X.

Gastroenterol Hepatol. 2020 Jan 2. pii: S0210-5705(19)30140-2. doi: 10.1016/j.gastrohep.2019.04.007. [Epub ahead of print] English, Spanish. No abstract available.

PMID:
31902599
2.

Higher seroprevalence of hepatitis E virus in autoimmune hepatitis: Role of false-positive antibodies.

Llovet LP, Gratacós-Ginés J, Ortiz O, Rodriguez-Tajes S, Lens S, Reverter E, Ruiz-Ortiz E, Costa J, Viñas O, Forns X, Parés A, Londoño MC.

Liver Int. 2019 Dec 21. doi: 10.1111/liv.14332. [Epub ahead of print]

PMID:
31863722
3.

The HBeAg-Negative "Gray Zone" Phase: A Frequent Condition With Different Outcomes in Western and Asian Patients?

Bonacci M, Forns X, Lens S.

Clin Gastroenterol Hepatol. 2020 Jan;18(1):263-264. doi: 10.1016/j.cgh.2019.05.024. No abstract available.

PMID:
31858983
4.

Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure.

Chen Q, Perales C, Soria ME, García-Cehic D, Gregori J, Rodríguez-Frías F, Buti M, Crespo J, Calleja JL, Tabernero D, Vila M, Lázaro F, Rando-Segura A, Nieto-Aponte L, Llorens-Revull M, Cortese MF, Fernandez-Alonso I, Castellote J, Niubó J, Imaz A, Xiol X, Castells L, Riveiro-Barciela M, Llaneras J, Navarro J, Vargas-Blasco V, Augustin S, Conde I, Rubín Á, Prieto M, Torras X, Margall N, Forns X, Mariño Z, Lens S, Bonacci M, Pérez-Del-Pulgar S, Londoño MC, García-Buey ML, Sanz-Cameno P, Morillas R, Martró E, Saludes V, Masnou-Ridaura H, Salmerón J, Quíles R, Carrión JA, Forné M, Rosinach M, Fernández I, García-Samaniego J, Madejón A, Castillo-Grau P, López-Núñez C, Ferri MJ, Durández R, Sáez-Royuela F, Diago M, Gimeno C, Medina R, Buenestado J, Bernet A, Turnes J, Trigo-Daporta M, Hernández-Guerra M, Delgado-Blanco M, Cañizares A, Arenas JI, Gomez-Alonso MJ, Rodríguez M, Deig E, Olivé G, Río OD, Cabezas J, Quiñones I, Roget M, Montoliu S, García-Costa J, Force L, Blanch S, Miralbés M, López-de-Goicoechea MJ, García-Flores A, Saumoy M, Casanovas T, Baliellas C, Gilabert P, Martin-Cardona A, Roca R, Barenys M, Villaverde J, Salord S, Camps B, Silvan di Yacovo M, Ocaña I, Sauleda S, Bes M, Carbonell J, Vargas-Accarino E, Ruzo SP, Guerrero-Murillo M, Von Massow G, Costafreda MI, López RM, González-Moreno L, Real Y, Acero-Fernández D, Viroles S, Pamplona X, Cairó M, Ocete MD, Macías-Sánchez JF, Estébanez A, Quer JC, Mena-de-Cea Á, Otero A, Castro-Iglesias Á, Suárez F, Vázquez Á, Vieito D, López-Calvo S, Vázquez-Rodríguez P, Martínez-Cerezo FJ, Rodríguez R, Macenlle R, Cachero A, Mereish G, Mora-Moruny C, Fábregas S, Sacristán B, Albillos A, Sánchez-Ruano JJ, Baluja-Pino R, Fernández-Fernández J, González-Portela C, García-Martin C, Sánchez-Antolín G, Andrade RJ, Simón MA, Pascasio JM, Romero-Gómez M, Antonio Del-Campo J, Domingo E, Esteban R, Esteban JI, Quer J.

Antiviral Res. 2019 Dec 16;174:104694. doi: 10.1016/j.antiviral.2019.104694. [Epub ahead of print]

PMID:
31857134
5.

Human chromosome-specific aneuploidy is influenced by DNA-dependent centromeric features.

Dumont M, Gamba R, Gestraud P, Klaasen S, Worrall JT, De Vries SG, Boudreau V, Salinas-Luypaert C, Maddox PS, Lens SM, Kops GJ, McClelland SE, Miga KH, Fachinetti D.

EMBO J. 2020 Jan 15;39(2):e102924. doi: 10.15252/embj.2019102924. Epub 2019 Nov 21.

PMID:
31750958
6.

Low seroprevalence and zero incidence rate of hepatitis E in men who have sex with men during a hepatitis A outbreak.

Rodríguez-Tajes S, Perpiñán E, Leonel T, Lens S, Mariño Z, Pérez-Del-Pulgar S, García-López M, Pocurull A, Koutsoudakis G, Forns X.

J Med Virol. 2019 Nov 19. doi: 10.1002/jmv.25630. [Epub ahead of print]

PMID:
31743439
7.

Long-term clinical outcomes in patients with chronic hepatitis delta: the role of persistent viraemia.

Palom A, Rodríguez-Tajes S, Navascués CA, García-Samaniego J, Riveiro-Barciela M, Lens S, Rodríguez M, Esteban R, Buti M.

Aliment Pharmacol Ther. 2020 Jan;51(1):158-166. doi: 10.1111/apt.15521. Epub 2019 Nov 13.

PMID:
31721254
8.

Efficacy and Safety of 8 Weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve, HCV-Infected Patients with APRI ≤ 1 in a Single-Arm, Open-Label, Multicenter Study.

Fontana RJ, Lens S, McPherson S, Elkhashab M, Ankoma-Sey V, Bondin M, Dos Santos AGP, Xue Z, Trinh R, Porcalla A, Zeuzem S.

Adv Ther. 2019 Dec;36(12):3458-3470. doi: 10.1007/s12325-019-01123-0. Epub 2019 Oct 23.

9.

Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals.

Pons M, Rodríguez-Tajes S, Esteban JI, Mariño Z, Vargas V, Lens S, Buti M, Augustin S, Forns X, Mínguez B, Genescà J.

J Hepatol. 2019 Oct 17. pii: S0168-8278(19)30606-3. doi: 10.1016/j.jhep.2019.10.005. [Epub ahead of print]

PMID:
31629779
10.

Impact of sustained virological response with DAAs on gastroesophageal varices and Baveno criteria in HCV-cirrhotic patients.

Puigvehí M, Londoño MC, Torras X, Lorente S, Vergara M, Morillas RM, Masnou H, Serrano T, Miquel M, Gallego A, Lens S, Carrión JA.

J Gastroenterol. 2019 Sep 6. doi: 10.1007/s00535-019-01619-0. [Epub ahead of print]

PMID:
31493238
11.

Efficacy and safety of direct-acting antivirals in older patients with cirrhosis and high comorbidity index.

Amoros-Reboredo P, Sotoca JM, Mariño Z, Rodríguez-Tajes S, Pocurull A, Soy D, Forns X, Lens S.

Eur J Gastroenterol Hepatol. 2019 Aug 20. doi: 10.1097/MEG.0000000000001518. [Epub ahead of print]

PMID:
31441796
12.

The frequency of SMN gene variants lacking exon 7 and 8 is highly population dependent.

Vijzelaar R, Snetselaar R, Clausen M, Mason AG, Rinsma M, Zegers M, Molleman N, Boschloo R, Yilmaz R, Kuilboer R, Lens S, Sulchan S, Schouten J.

PLoS One. 2019 Jul 24;14(7):e0220211. doi: 10.1371/journal.pone.0220211. eCollection 2019.

13.

Incidence of depression in patients with hepatitis C treated with direct-acting antivirals.

Egmond E, Mariño Z, Navines R, Oriolo G, Pla A, Bartres C, Lens S, Forns X, Martin-Santos R.

Braz J Psychiatry. 2019 Jul 15. pii: S1516-44462019005012103. doi: 10.1590/1516-4446-2018-0336. [Epub ahead of print]

14.

Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs.

Llaneras J, Riveiro-Barciela M, Lens S, Diago M, Cachero A, García-Samaniego J, Conde I, Arencibia A, Arenas J, Gea F, Torras X, Luis Calleja J, Antonio Carrión J, Fernández I, María Morillas R, Rosales JM, Carmona I, Fernández-Rodríguez C, Hernández-Guerra M, Llerena S, Bernal V, Turnes J, González-Santiago JM, Montoliu S, Figueruela B, Badia E, Delgado M, Fernández-Bermejo M, Iñarrairaegui M, Pascasio JM, Esteban R, Mariño Z, Buti M.

J Hepatol. 2019 Oct;71(4):666-672. doi: 10.1016/j.jhep.2019.06.002. Epub 2019 Jun 14.

PMID:
31203153
15.

PLK1 plays dual roles in centralspindlin regulation during cytokinesis.

Adriaans IE, Basant A, Ponsioen B, Glotzer M, Lens SMA.

J Cell Biol. 2019 Apr 1;218(4):1250-1264. doi: 10.1083/jcb.201805036. Epub 2019 Feb 6.

16.

Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules.

Mariño Z, Darnell A, Lens S, Sapena V, Díaz A, Belmonte E, Perelló C, Calleja JL, Varela M, Rodriguez M, Rodriguez de Lope C, Llerena S, Torras X, Gallego A, Sala M, Morillas RM, Minguez B, Llaneras J, Coll S, Carrion JA, Iñarrairaegui M, Sangro B, Vilana R, Sole M, Ayuso C, Ríos J, Forns X, Bruix J, Reig M.

J Hepatol. 2019 May;70(5):874-884. doi: 10.1016/j.jhep.2019.01.005. Epub 2019 Jan 24.

PMID:
30684506
17.

Simplified follow-up of patients with mild chronic hepatitis C in areas with limited access to antiviral therapy.

Lens S, Torres F, Bonacci M, Bartres C, Pocurull A, Mariño Z, Londoño MC, Rodríguez-Tajes S, Forns X.

Dig Liver Dis. 2019 Jun;51(6):875-881. doi: 10.1016/j.dld.2018.11.019. Epub 2018 Nov 29.

PMID:
30558865
18.

Cytokinesis defects and cancer.

Lens SMA, Medema RH.

Nat Rev Cancer. 2019 Jan;19(1):32-45. doi: 10.1038/s41568-018-0084-6. Review.

PMID:
30523339
19.

Early HCV viral kinetics under DAAs may optimize duration of therapy in patients with compensated cirrhosis.

Gambato M, Canini L, Lens S, Graw F, Perpiñan E, Londoño MC, Uprichard SL, Mariño Z, Reverter E, Bartres C, González P, Pla A, Costa J, Burra P, Cotler SJ, Forns X, Dahari H.

Liver Int. 2019 May;39(5):826-834. doi: 10.1111/liv.14014. Epub 2018 Dec 28.

PMID:
30499631
20.

Editorial: STAT-4 polymorphism - a tool to personalise clinical practice in chronic HBV infection.

Bonacci M, Lens S.

Aliment Pharmacol Ther. 2018 Oct;48(7):768-769. doi: 10.1111/apt.14924. No abstract available.

PMID:
30246310
21.

Eight weeks of Paritaprevir/r/Ombitasvir + Dasabuvir in HCV genotype 1b with mild-moderate fibrosis: Results from a real-world cohort.

Puigvehí M, De Cuenca B, Viu A, Diago M, Turnes J, Gea F, Pascasio JM, Lens S, Cabezas J, Badia E, Olveira A, Morillas RM, Torras X, Montoliu S, Cordero P, Castro JL, Salmerón J, Molina E, Sánchez-Ruano JJ, Moreno J, Antón MD, Moreno JM, De la Vega J, Calleja JL, Carrión JA.

Liver Int. 2019 Jan;39(1):90-97. doi: 10.1111/liv.13950. Epub 2018 Nov 12.

PMID:
30160363
22.

Hepatitis C virus early kinetics and resistance-associated substitution dynamics during antiviral therapy with direct-acting antivirals.

Perpiñán E, Caro-Pérez N, García-González N, Gregori J, González P, Bartres C, Soria ME, Perales C, Lens S, Mariño Z, Londoño MC, Ariza X, Koutsoudakis G, Quer J, González-Candelas F, Forns X, Pérez-Del-Pulgar S.

J Viral Hepat. 2018 Dec;25(12):1515-1525. doi: 10.1111/jvh.12986. Epub 2018 Oct 4.

PMID:
30141252
23.

Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis.

Esteban R, Pineda JA, Calleja JL, Casado M, Rodríguez M, Turnes J, Morano Amado LE, Morillas RM, Forns X, Pascasio Acevedo JM, Andrade RJ, Rivero A, Carrión JA, Lens S, Riveiro-Barciela M, McNabb B, Zhang G, Camus G, Stamm LM, Brainard DM, Subramanian GM, Buti M.

Gastroenterology. 2018 Oct;155(4):1120-1127.e4. doi: 10.1053/j.gastro.2018.06.042. Epub 2018 Jun 27.

PMID:
29958855
24.

Hepatitis E-induced acute-on-chronic liver failure and VI nerve paralysis.

Jung G, Olivas P, Díaz A, Lens S.

Liver Int. 2018 Sep;38(9):1696-1697. doi: 10.1111/liv.13897. Epub 2018 Jul 15. No abstract available.

PMID:
29885028
25.

Long-Term Outcomes of Patients With HCV-Associated Cryoglobulinemic Vasculitis After Virologic Cure.

Bonacci M, Lens S, Mariño Z, Londoño MC, Rodriguez-Tajes S, Sánchez-Tapias JM, Ramos-Casals M, Hernández-Rodríguez J, Forns X.

Gastroenterology. 2018 Aug;155(2):311-315.e6. doi: 10.1053/j.gastro.2018.04.024. Epub 2018 Apr 26.

PMID:
29705529
26.

Safety of hepatitis C virus (HCV)-treated donors for kidney transplantation excluding occult HCV infection through kidney biopsies.

Gelpi R, Rodríguez-Villar C, Paredes D, Roque R, Ruiz A, Adalia R, de Sousa E, Revuelta I, Sole M, Martinez M, Navarro M, Lens S, Oppenheimer F, Diekmann F.

Transpl Int. 2018 Aug;31(8):938-939. doi: 10.1111/tri.13270. Epub 2018 May 11. No abstract available.

27.

Shorter hepatitis B immunoglobulin administration is not associated to hepatitis B virus recurrence when receiving combined prophylaxis after liver transplantation.

Lens S, García-Eliz M, Fernández I, Castells L, Bonacci M, Mas A, Crespo G, Buti M, Prieto M, Forns X.

Liver Int. 2018 Nov;38(11):1940-1950. doi: 10.1111/liv.13858. Epub 2018 May 3.

PMID:
29660249
28.

Anti-viral therapy can be delayed or avoided in a significant proportion of HBeAg-negative Caucasian patients in the Grey Zone.

Bonacci M, Lens S, Mariño Z, Londoño MC, Rodríguez-Tajes S, Mas A, García-López M, Pérez-Del-Pulgar S, Sánchez-Tapias JM, Forns X.

Aliment Pharmacol Ther. 2018 May;47(10):1397-1408. doi: 10.1111/apt.14613. Epub 2018 Mar 25.

29.

Reply.

Lens S, Forns X, García-Pagán JC.

Gastroenterology. 2018 Apr;154(5):1551-1552. doi: 10.1053/j.gastro.2018.03.017. Epub 2018 Mar 8. No abstract available.

PMID:
29526729
30.

The Ins and Outs of Aurora B Inner Centromere Localization.

Hindriksen S, Lens SMA, Hadders MA.

Front Cell Dev Biol. 2017 Dec 22;5:112. doi: 10.3389/fcell.2017.00112. eCollection 2017. Review.

31.

Aurora A kinase phosphorylates Hec1 to regulate metaphase kinetochore-microtubule dynamics.

DeLuca KF, Meppelink A, Broad AJ, Mick JE, Peersen OB, Pektas S, Lens SMA, DeLuca JG.

J Cell Biol. 2018 Jan 2;217(1):163-177. doi: 10.1083/jcb.201707160. Epub 2017 Nov 29.

32.

Evolution of acute hepatitis C virus infection in a large European city: Trends and new patterns.

Garriga C, Manzanares-Laya S, García de Olalla P, Gorrindo P, Lens S, Solà R, Martínez-Rebollar M, Laguno M, Navarro J, Torras X, Gurguí M, Barberá MJ, Quer J, Masdeu E, Simón P, Ros M, de Andrés A, Caylà JA.

PLoS One. 2017 Nov 14;12(11):e0187893. doi: 10.1371/journal.pone.0187893. eCollection 2017.

33.

Potential drug-drug interactions of OMBITASVIR, PARITAPREVIR/ritonavir ± DASABUVIR ± ribavirin in clinical practice.

González-Colominas E, Londoño MC, Morillas RM, Torras X, Mojal S, Lens S, López D, Gallego A, Mariño Z, Ardèvol M, Pagès N, Solà R, Carrión JA.

J Gastroenterol Hepatol. 2018 May;33(5):1100-1107. doi: 10.1111/jgh.14014. Epub 2018 Feb 12.

PMID:
28994141
34.

Hepatitis A outbreak in Barcelona among men who have sex with men (MSM), January-June 2017: A hospital perspective.

Rodríguez-Tajes S, Perpiñán E, Caballol B, Lens S, Mariño Z, Costa J, Vilella A, Pérez-Del-Pulgar S, Forns X, Koutsoudakis G.

Liver Int. 2018 Apr;38(4):588-593. doi: 10.1111/liv.13606. Epub 2017 Nov 10.

PMID:
28980376
35.

Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial.

Forns X, Lee SS, Valdes J, Lens S, Ghalib R, Aguilar H, Felizarta F, Hassanein T, Hinrichsen H, Rincon D, Morillas R, Zeuzem S, Horsmans Y, Nelson DR, Yu Y, Krishnan P, Lin CW, Kort JJ, Mensa FJ.

Lancet Infect Dis. 2017 Oct;17(10):1062-1068. doi: 10.1016/S1473-3099(17)30496-6. Epub 2017 Aug 14.

PMID:
28818546
36.

Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis.

Lens S, Alvarado-Tapias E, Mariño Z, Londoño MC, LLop E, Martinez J, Fortea JI, Ibañez L, Ariza X, Baiges A, Gallego A, Bañares R, Puente A, Albillos A, Calleja JL, Torras X, Hernández-Gea V, Bosch J, Villanueva C, Forns X, García-Pagán JC.

Gastroenterology. 2017 Nov;153(5):1273-1283.e1. doi: 10.1053/j.gastro.2017.07.016. Epub 2017 Jul 20.

PMID:
28734831
37.

Baculoviral delivery of CRISPR/Cas9 facilitates efficient genome editing in human cells.

Hindriksen S, Bramer AJ, Truong MA, Vromans MJM, Post JB, Verlaan-Klink I, Snippert HJ, Lens SMA, Hadders MA.

PLoS One. 2017 Jun 22;12(6):e0179514. doi: 10.1371/journal.pone.0179514. eCollection 2017.

38.

Interferon-Free Therapy in Elderly Patients With Advanced Liver Disease.

Lens S, Fernández I, Rodríguez-Tajes S, Hontangas V, Vergara M, Forné M, Calleja JL, Diago M, Llaneras J, Llerena S, Torras X, Sacristán B, Roget M, Fernández-Rodríguez CM, Navascués MC, Fuentes J, Sánchez-Ruano JJ, Simón MÁ, Sáez-Royuela F, Baliellas C, Morillas R, Forns X; Spanish Group for the Study of the Use of Direct-acting Drugs Hepatitis C Collaborating Group.

Am J Gastroenterol. 2017 Sep;112(9):1400-1409. doi: 10.1038/ajg.2017.157. Epub 2017 Jun 6.

PMID:
28585554
39.

Inner centromere localization of the CPC maintains centromere cohesion and allows mitotic checkpoint silencing.

Hengeveld RCC, Vromans MJM, Vleugel M, Hadders MA, Lens SMA.

Nat Commun. 2017 May 31;8:15542. doi: 10.1038/ncomms15542.

40.

Treating Hepatitis C in Patients with Renal Failure.

Lens S, Rodriguez-Tajes S, Llovet LP, Maduell F, Londoño MC.

Dig Dis. 2017;35(4):339-346. doi: 10.1159/000456585. Epub 2017 May 3. Review.

PMID:
28467997
41.

Real-World Effectiveness and Safety of Oral Combination Antiviral Therapy for Hepatitis C Virus Genotype 4 Infection.

Crespo J, Calleja JL, Fernández I, Sacristan B, Ruiz-Antorán B, Ampuero J, Hernández-Conde M, García-Samaniego J, Gea F, Buti M, Cabezas J, Lens S, Morillas RM, Salcines JR, Pascasio JM, Turnes J, Sáez-Royuela F, Arenas J, Rincón D, Prieto M, Jorquera F, Sanchez Ruano JJ, Navascués CA, Molina E, Moya AG, Moreno-Planas JM; Spanish Group for the Study of the Use of Direct-acting Drugs Hepatitis C Collaborating Group.

Clin Gastroenterol Hepatol. 2017 Jun;15(6):945-949.e1. doi: 10.1016/j.cgh.2017.02.020. Epub 2017 Feb 24.

PMID:
28238958
42.

Aplastic Anemia and Severe Myelosuppression with Boceprevir or Simeprevir-Containing Hepatitis C Virus Treatment.

Senín A, Broquetas T, Cañete N, Lens S, Londoño MC, Ferraro M, Forns X, Salar A, Carrión JA.

Ann Hepatol. 2017 March-April;16(2):312-317. doi: 10.5604/16652681.1231593.

43.

Hepatitis B reactivation in patients with chronic hepatitis C undergoing anti-viral therapy with an interferon-free regimen.

Londoño MC, Lens S, Mariño Z, Bonacci M, Ariza X, Broquetas T, Pla A, Bartres C, Adriani MV, Rodríguez-Tajes S, Costa J, Carrión JA, Pérez-Del-Pulgar S, Forns X.

Aliment Pharmacol Ther. 2017 Apr;45(8):1156-1161. doi: 10.1111/apt.13985. Epub 2017 Feb 16.

44.

Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.

Calleja JL, Crespo J, Rincón D, Ruiz-Antorán B, Fernandez I, Perelló C, Gea F, Lens S, García-Samaniego J, Sacristán B, García-Eliz M, Llerena S, Pascasio JM, Turnes J, Torras X, Morillas RM, Llaneras J, Serra MA, Diago M, Rodriguez CF, Ampuero J, Jorquera F, Simon MA, Arenas J, Navascues CA, Bañares R, Muñoz R, Albillos A, Mariño Z; Spanish Group for the Study of the Use of Direct-acting Drugs Hepatitis C Collaborating Group.

J Hepatol. 2017 Jun;66(6):1138-1148. doi: 10.1016/j.jhep.2017.01.028. Epub 2017 Feb 9.

PMID:
28189751
45.

Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry.

Fernández Carrillo C, Lens S, Llop E, Pascasio JM, Crespo J, Arenas J, Fernández I, Baliellas C, Carrión JA, de la Mata M, Buti M, Castells L, Albillos A, Romero M, Turnes J, Pons C, Moreno-Planas JM, Moreno-Palomares JJ, Fernández-Rodriguez C, García-Samaniego J, Prieto M, Fernández Bermejo M, Salmerón J, Badia E, Salcedo M, Herrero JI, Granados R, Blé M, Mariño Z, Calleja JL.

Hepatology. 2017 Jun;65(6):1810-1822. doi: 10.1002/hep.29097. Epub 2017 Apr 28.

PMID:
28170112
46.

Correction: Neutrophil and Monocyte Function in Patients with Chronic Hepatitis C Undergoing Antiviral Therapy with Regimens Containing Protease Inhibitors with and without Interferon.

Gambato M, Caro-Pérez N, González P, Cañete N, Mariño Z, Lens S, Bonacci M, Bartres C, Sánchez-Tapias JM, Carrión JA, Forns X, Juan M, Pérez-Del-Pulgar S, Londoño MC.

PLoS One. 2017 Jan 20;12(1):e0170913. doi: 10.1371/journal.pone.0170913. eCollection 2017.

47.

Effectiveness and Safety of Entecavir or Tenofovir in a Spanish Cohort of Chronic Hepatitis B Patients: Validation of the Page-B Score to Predict Hepatocellular Carcinoma.

Riveiro-Barciela M, Tabernero D, Calleja JL, Lens S, Manzano ML, Rodríguez FG, Crespo J, Piqueras B, Pascasio JM, Comas C, Gutierrez ML, Aguirre A, Suárez E, García-Samaniego J, Rivero M, Acero D, Fernandez-Bermejo M, Moreno D, Sánchez-Pobre P, de Cuenca B, Moreno-Palomares JJ, Esteban R, Buti M.

Dig Dis Sci. 2017 Mar;62(3):784-793. doi: 10.1007/s10620-017-4448-7. Epub 2017 Jan 11.

PMID:
28078526
48.

Aplastic Anemia and Severe Myelosuppression with Boceprevir or Simeprevir-Containing Hepatitis C Virus Treatment.

Senín A, Broquetas T, Lens S, Cañete N, Londoño MC, Ferraro M, Forns X, Salar A, Carrión JA.

Ann Hepatol. 2017 Mar - Apr;16(2):312-317. doi: 10.5604/16652681.1231595.

49.

Clinico-biological characteristics and outcome of hepatitis C virus-positive patients with diffuse large B-cell lymphoma treated with immunochemotherapy.

Dlouhy I, Torrente MÁ, Lens S, Rovira J, Magnano L, Giné E, Delgado J, Balagué O, Martínez A, Campo E, Forns X, Sánchez-Tapias JM, López-Guillermo A.

Ann Hematol. 2017 Mar;96(3):405-410. doi: 10.1007/s00277-016-2903-8. Epub 2016 Dec 29.

PMID:
28035434
50.

Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection.

Perelló C, Carrión JA, Ruiz-Antorán B, Crespo J, Turnes J, Llaneras J, Lens S, Delgado M, García-Samaniego J, García-Paredes F, Fernández I, Morillas RM, Rincón D, Porres JC, Prieto M, Lázaro Ríos M, Fernández-Rodríguez C, Hermo JA, Rodríguez M, Herrero JI, Ruiz P, Fernández JR, Macías M, Pascasio JM, Moreno JM, Serra MÁ, Arenas J, Real Y, Jorquera F, Calleja JL; Spanish Collaborative Group for the Study of the Use of Hepatitis C Direct-Acting Drugs.

J Viral Hepat. 2017 Mar;24(3):226-237. doi: 10.1111/jvh.12637. Epub 2016 Dec 15.

PMID:
27976491

Supplemental Content

Support Center